{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:40:07Z","timestamp":1752252007764,"version":"3.41.2"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2024,10,14]]},"abstract":"<jats:p>Aim: Retinal detachment is an acute sight-threatening condition that requires immediate surgical intervention. The aim of this study is to compare the outcomes of pars plana vitrectomy (PPV) for uncomplicated rhegmatogenous retinal detachment (RRD) between the different types of gases used, the position, and the number of tears.\n\nMaterial and Methods: This is a retrospective non-randomized comparative study of patients with uncomplicated RRD treated at the Department of Ophthalmology from March 2018 to April 2021 using PPV. A total of 494 evaluated eyes were included in the study. The anatomical success of the surgery was monitored with regard to the extent of retinal detachment, the number and position of tears, and the tamponade used.\n\nResults: The success rate of retinal reattachment with a single operation was 90.7% (448 eyes), and the final anatomical success rate was 100%. A very weak paired relationship was found between the success of the surgery for tears in the 4\u20138 hours region and the 9\u20133 hours region (89.1% vs. 92%). Similarly, no significant differences were observed between procedures using SF6 and C3F8 gases for RRD with a tear in the 4\u20138 hours region (success rate 93.4% for SF6 vs. 89.1% for C3F8). The average postoperative improvement of best corrected visual acuity was 29.6 ETDRS letters, and a gain of 15 letters was recorded in 55.1% (272 eyes). Overall, the complication rate was very low.\n\nConclusion: PPV is a safe and effective method for treating RRD. Extensive experience with this method allows the use of short-acting tamponades in selected patients.<\/jats:p>","DOI":"10.31348\/2024\/41","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:08:31Z","timestamp":1737450511000},"source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Retinal Tear Location and Internal Tamponade on The Success of Pars Plana Vitrectomy in Patients with Uncomplicated Retinal Detachment"],"prefix":"10.31348","volume":"81","author":[{"given":"Zbyn\u011bk","family":"Stra\u0148\u00e1k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Dobaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pen\u010d\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Helman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Studen\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9-vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Thi-rd Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031","DOI":"10.1016\/j.ophtha.2021.10.021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Ear-ly Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Ear-ly Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prema-turity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in pre-mature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pedi-atric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591","DOI":"10.2147\/phmt.s391591"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Reti-nopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302","DOI":"10.1097\/apo.0000000000000302"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Re-cent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prema-turity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3)","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:17:46Z","timestamp":1752250666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,15]]},"published-print":{"date-parts":[[2025,3,15]]}},"URL":"https:\/\/doi.org\/10.31348\/2024\/41","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"type":"electronic","value":"1805-4447"},{"type":"print","value":"1211-9059"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}